ROCHE I (RO.SW)

ROCHE I achieves an AlphaScore of 73/100, indicating a buy recommendation within the healthcare sector as of October 11, 2026. Fundamental highlights include a return on equity (ROE) of 38.11 and a gross margin of 73.73. A major strength is its high quality sub-score and strong net margin of 20.33, ensuring robust operational efficiency. A key risk is its higher debt-to-equity ratio of 0.91, suggesting increased financial obligations. Evidence is limited to the supplied record.

Written 11/10/2026, 00:43:34 UTC · Snapshot 11/10/2026